Efficacy and safety of XKH004, a novel dual interleukin-17A/F inhibitory monoclonal antibody, in active ankylosing spondylitis: A 52-week phase 3 randomized study

hLife · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles